AngioDynamics (NASDAQ:ANGO) Price Target Raised to $15.00

AngioDynamics (NASDAQ:ANGO) had its price objective increased by HC Wainwright from $14.00 to $15.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

Separately, Canaccord Genuity Group lowered their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

AngioDynamics Stock Performance

Shares of ANGO opened at $12.30 on Friday. AngioDynamics has a 52-week low of $5.26 and a 52-week high of $13.13. The business’s fifty day moving average is $8.23 and its 200-day moving average is $7.45. The firm has a market cap of $499.80 million, a price-to-earnings ratio of -2.02 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company’s revenue was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. As a group, research analysts forecast that AngioDynamics will post -0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On AngioDynamics

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in AngioDynamics by 110.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock worth $1,240,000 after purchasing an additional 83,622 shares in the last quarter. State Street Corp raised its stake in shares of AngioDynamics by 2.7% in the third quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock valued at $6,305,000 after buying an additional 21,218 shares during the period. First Eagle Investment Management LLC purchased a new stake in AngioDynamics during the second quarter valued at about $1,321,000. Systematic Financial Management LP lifted its stake in shares of AngioDynamics by 8.4% during the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after buying an additional 162,972 shares in the last quarter. Finally, CWM LLC lifted its position in shares of AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after acquiring an additional 8,832 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.